Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI-522 · 7 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | MEDI-522 + Docetaxel + Prednisone + Zoledronic Acid (N=55) |
| 2 | OTHER | Docetaxel + Prednisone + Zoledronic Acid (N=55) |
| MEDI-522 | EXPERIMENTAL | Drug |
| 3 | EXPERIMENTAL | MEDI-522 |
| 4 | EXPERIMENTAL | MEDI-522 |
| 5 | EXPERIMENTAL | MEDI-522 |
| Name | Type | Description |
|---|---|---|
| MEDI-522 | BIOLOGICAL | IV at a concentration of 50 mg/mL and 10mL vials |
| Docetaxel + Prednisone* + Zoledronic Acid | BIOLOGICAL | IV 75 mg/m2 IV 3-4 mg 5 mg |
| Placebo | OTHER | 4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0) |
| MEDI--522 | BIOLOGICAL | IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL. |
| Integrin + Dacarbazine | BIOLOGICAL | supplied in other formulations |
Inclusion Criteria: * Adult men at least 18 years of age at the time of randomization. * Metastatic, histologically or cytologically confirmed adenocarcinoma of the prostate that has progressed after start of androgen deprivation therapy, which includes prior orchiectomy or medical castration using...
Top 20 of 51 competitors
MEDI-522 is an investigational small molecule being studied for use in oncology and inflammatory conditions. Its clinical development has focused on malignant melanoma, metastatic melanoma, refractory solid tumors, and irinotecan-refractory advanced colorectal cancer. It has also been explored for psoriasis, prostate cancer, and rheumatoid arthritis, though no approved indication exists.
MEDI-522 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The drug is an investigational small molecule that has been evaluated in clinical trials for multiple cancer types, including melanoma and colorectal cancer.
MEDI-522 is in Phase 1 clinical development. It has completed Phase 1 trials in patients with advanced malignant melanoma, refractory solid tumors, and irinotecan-refractory advanced colorectal cancer. The drug is investigational and has not been approved by regulatory authorities for any use.
MEDI-522 has completed several clinical trials, including NCT00066196, a Phase 2 study of MEDI-522 with or without dacarbazine in metastatic melanoma; NCT00111696, a Phase 1 tumor saturation study in advanced malignant melanoma; NCT00263783, a Phase 1 trial in refractory solid tumors; and NCT00284817, a Phase 1 study in irinotecan-refractory colorectal cancer.
Yes, MEDI-522 is also known as Abergrin. In clinical trial records, the drug is referred to by both names, with the Phase 1 study NCT00111696 titled 'Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma.'
MEDI-522 is a small molecule, but its specific molecular target has not been disclosed in the available clinical trial information. The drug has been studied for its antitumor activity in melanoma and other solid tumors, as well as for potential effects in inflammatory conditions like rheumatoid arthritis and psoriasis.